Despite industry outcry, new data question how relevant the rule would have been anyway.
The US regulator’s restrictions spell trouble for the Jak inhibitor class – though there will be beneficiaries.
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
A US advisory panel has largely endorsed three anti-PD-(L)1 drugs, with voting apparently driven by the availability of alternatives.
Confusion over blood clot numbers with all four approved Covid-19 vaccines could cause more vaccine hesitancy.
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.